By Disease Area
- Cardiovascular Diseases
- Renal Diseases
- Others
By Application
- Drug Delivery
- Molecular Imaging
- Stem Cell Delivery
- Gene Therapy
By Region
- North America
- Europe
- Asia-Pacific
- Latin America
- Middle East and Africa
The market is classified into disease area, application and region. The disease area segment is fragmented into renal diseases, cardiovascular diseases and others. The cardiovascular disease segment is anticipated to account for the largest microbubbles or ultrasound contrast agents market share and this can be credited to a rise in the number of patients diagnosed with cardiovascular diseases, increased adoption of microbubbles in echocardiogram procedures for obtaining an optimum echocardiogram to effectively analyse the issue. The application segment is bifurcated into drug delivery, molecular imaging, stem cell delivery and gene therapy. The molecular imaging segment is anticipated to lead the market, and this can be attributed to an increased acceptance of microbubbles in different diagnostic procedures that are based on ultrasound technology. Furthermore, a rising necessity for monitoring the biomarker status in imaging inflammation, vascular endothelium and visualizing the vasculature of a tumor has boosted the proliferation of the market.
The North America region is predicted to dominate the market, and this is due to the increased cancer patient population along with a rise in the adoption of ultrasound procedures integrated with microbubbles. Furthermore, a strong presence of key market players has bolstered the market growth in the region. However, the Asia Pacific region is predicted to grow at substantial rate and this growth will be mainly driven by countries like India, Japan, South Korea with a rise in the awareness programs undertaken by the government bodies for improving public health and advancements in the healthcare infrastructure developed in the region.